The lack of CD8+ tumor-infiltrating lymphocytes in the tumor microenvironment, lower PD-L1 expression and overactivated oncogenic pathway may be possible explannations for the lack of efficacy of PD-L1 inhibitors in these populations (Gainor et al., 2016; Lin et al., 2019). This evidence concerns the gene CD274 and neoplasm.